Unicycive Therapeutics (UNCY) Long-Term Debt Issuances (2020 - 2021)
Unicycive Therapeutics' (UNCY) quarterly Long-Term Debt Issuances came in at $88000.0 in Q2 2021, down 91.29% on a QoQ basis from $1.0 million in Q1 2021.
Unicycive Therapeutics (UNCY) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends
Unicycive Therapeutics (UNCY) has 2 years of Long-Term Debt Issuances data on file, last reported at $88000.0 in Q2 2021.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $88000.0 in Q2 2021, while the trailing twelve-month figure through Dec 2021 was $1.1 million (changed N/A YoY) and the FY2021 annual result came in at $1.1 million, down 14.88% from the prior year.
- Long-Term Debt Issuances retreated to $88000.0 in Q2 2021, from $1.0 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $1.0 million in Q1 2021 to a low of $88000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 88,000.00 |
| Jun 30, 2021 | 88,000.00 |
| Mar 31, 2021 | 1.01 Mn |
| Mar 31, 2021 | 1.01 Mn |
| Dec 31, 2020 | 390,000.00 |
| Dec 31, 2020 | 390,000.00 |